855 related articles for article (PubMed ID: 26753693)
21. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
[TBL] [Abstract][Full Text] [Related]
22. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.
Harris LA; Baffy N
Postgrad Med; 2017 Nov; 129(8):872-888. PubMed ID: 28936910
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in pharmacological treatment of irritable bowel syndrome.
Lazaraki G; Chatzimavroudis G; Katsinelos P
World J Gastroenterol; 2014 Jul; 20(27):8867-85. PubMed ID: 25083060
[TBL] [Abstract][Full Text] [Related]
24. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.
Lacy BE; Chang L; Rao SSC; Heimanson Z; Sayuk GS
Clin Ther; 2023 Mar; 45(3):198-209. PubMed ID: 36922331
[TBL] [Abstract][Full Text] [Related]
25. A Narrative Review of Irritable Bowel Syndrome with Diarrhea: A Primer for Primary Care Providers.
Moshiree B; Heidelbaugh JJ; Sayuk GS
Adv Ther; 2022 Sep; 39(9):4003-4020. PubMed ID: 35869354
[TBL] [Abstract][Full Text] [Related]
26. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
Nee J; Zakari M; Lembo AJ
Expert Opin Pharmacother; 2015; 16(18):2781-92. PubMed ID: 26558923
[TBL] [Abstract][Full Text] [Related]
27. Modern Management of Irritable Bowel Syndrome: More Than Motility.
Tack J; Vanuytsel T; Corsetti M
Dig Dis; 2016; 34(5):566-73. PubMed ID: 27331917
[TBL] [Abstract][Full Text] [Related]
28. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
Liu R; Staller K
Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
[TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.
Schoenfeld P; Pimentel M; Chang L; Lembo A; Chey WD; Yu J; Paterson C; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2014 May; 39(10):1161-8. PubMed ID: 24697851
[TBL] [Abstract][Full Text] [Related]
30. Clinical trials in irritable bowel syndrome: a review.
Ervin CM; Mangel AW
Rev Recent Clin Trials; 2013 Mar; 8(1):9-22. PubMed ID: 23130604
[TBL] [Abstract][Full Text] [Related]
31. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.
Meyrat P; Safroneeva E; Schoepfer AM
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1084-93. PubMed ID: 23066911
[TBL] [Abstract][Full Text] [Related]
32. Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials.
Li J; Zhu W; Liu W; Wu Y; Wu B
Medicine (Baltimore); 2016 Jan; 95(4):e2534. PubMed ID: 26825893
[TBL] [Abstract][Full Text] [Related]
33. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota.
Jin Y; Ren X; Li G; Li Y; Zhang L; Wang H; Qian W; Hou X
J Gastroenterol Hepatol; 2018 Feb; 33(2):443-452. PubMed ID: 28573746
[TBL] [Abstract][Full Text] [Related]
34. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome.
Zhuang X; Tian Z; Luo M; Xiong L
BMC Gastroenterol; 2020 Jun; 20(1):187. PubMed ID: 32532214
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.
Black CJ; Burr NE; Camilleri M; Earnest DL; Quigley EM; Moayyedi P; Houghton LA; Ford AC
Gut; 2020 Jan; 69(1):74-82. PubMed ID: 30996042
[TBL] [Abstract][Full Text] [Related]
36. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
Fukudo S; Ida M; Akiho H; Nakashima Y; Matsueda K
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):953-9.e4. PubMed ID: 24315882
[TBL] [Abstract][Full Text] [Related]
37. Use of rifaximin in gastrointestinal and liver diseases.
Shayto RH; Abou Mrad R; Sharara AI
World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007
[TBL] [Abstract][Full Text] [Related]
38. Effects of two natural medicine formulations on irritable bowel syndrome symptoms: a pilot study.
Hawrelak JA; Myers SP
J Altern Complement Med; 2010 Oct; 16(10):1065-71. PubMed ID: 20954962
[TBL] [Abstract][Full Text] [Related]
39. Rifaximin and lubiprostone: the best options for treating irritable bowel syndrome?
Purslow C
Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):263. PubMed ID: 22816171
[No Abstract] [Full Text] [Related]
40. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]